J&J: CHMP approves Amivantamab
(CercleFinance.com) - Johnson & Johnson's Janssen Pharmaceuticals has announced that the Committee for Medicinal Products for Human Use (CHMP) has approved amivantamab for the treatment of patients with advanced non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, after failure of platinum-based therapy.
If approved, amivantamab will be the first treatment in the European Union to specifically target EGFR exon 20 insertion mutations for advanced NSCLC, it said.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
If approved, amivantamab will be the first treatment in the European Union to specifically target EGFR exon 20 insertion mutations for advanced NSCLC, it said.
Copyright (c) 2021 CercleFinance.com. All rights reserved.